经导管肝动脉化疗栓塞联合门静脉化疗栓塞治疗肝癌伴门静脉癌栓临床价值的Meta分析  

Meta-analysis of transcatheter arterial chemoembolization combined portal vein chemoembolization for hepatocellular carcinoma complicated by portal vein tumor thrombus

作　　者：黄笛 龙潭 刘豪杰 郭伟昌[2] 李昭辉[2] Huang Di;Long Tan;Liu Haojie;Guo Weichang;Li Zhaohui(Department of Clinical Medicine,Chengdu Medical College,Chengdu 610500,Sichuan,China;Department of Vascular Surgery,the First People's Hospital of Yibin,Yibin 644000,Sichuan,China)

机构地区：[1]成都医学院临床医学院,四川成都610500 [2]宜宾市第一人民医院血管外科,四川宜宾644000

出　　处：《血管与腔内血管外科杂志》2023年第4期434-440,共7页Journal of Vascular and Endovascular Surgery

摘　　要：目的 系统评价经导管肝动脉化疗栓塞(TACE)联合门静脉化疗栓塞(PVCE)与单纯TACE治疗肝癌伴门静脉癌栓的临床价值。方法 采用计算机检索PubMed、Embase、Medline、Cochrane Library、Web of Science、维普中文科技期刊数据库、万方数据库、中国知网、中国生物医学文献数据库等,检索TACE联合PVCE与单纯TACE治疗肝癌伴门静脉癌栓的相关研究,分析患者的生存率及术后不良反应发生情况。检索时限为建库至2022年3月14日,由2名评价者独立筛选文献、提取数据,参照Cochrane协作网提供的偏倚风险评估工具对文献质量进行评估。结果 共纳入10篇目标文献,共681例肝癌伴门静脉癌栓患者。Meta分析结果显示,TACE联合PVCE组患者的1、2、3年生存率及不良反应发生率均高于单纯TACE组患者(P﹤0.05)。结论 与单纯TACE治疗肝癌伴门静脉癌栓相比,TACE联合PVCE治疗的临床价值更高,不良反应发生率更低。Objective To systemically evaluate the clinical value of transcatheter arterial chemoembolization(TACE)combined portal vein chemoembolization(PVCE)versus single TACE in treating hepatocellular carcinoma complicated by portal vein tumor thrombus.Method PubMed,Embase,Medline,Cochrane Library,Web of Science,VIP,Wan Fang Database,China National Knowledge Internet and Chinese Biomedical Literature Database(CBM)were searched for the studies on the survival rate and postoperative adverse reactions of TACE+PVCE versus single TACE in treating hepatocellular carcinoma complicated by portal vein tumor thrombus with the cut-off date from establishment of database to March 14,2022.The articles were screened and data were extracted by two independent reviewers.The quality of literatures was evaluated according to the risk assessment tool for bias provided by the Cochrane Collaboration.Result Ten articles containing 681 hepatocellular carcinoma complicated by portal vein tumor thrombus patients were included in this research.Meta-analysis showed that the one-year,two-year and three-year survival rates and the incidence rate of adverse reaction of TACE+PVCE group were higher than those in TACE group(P<0.05).Conclusion The clinical value of TACE+PVCE in treating hepatocellular carcinoma complicated by portal vein tumor thrombus is higher and incidence of adverse reactions lower than that of single TACE.

关 键 词：肝动脉化疗栓塞 门静脉化疗栓塞 肝癌 门静脉癌栓 临床价值 META分析 

分 类 号：R543[医药卫生—心血管疾病]